Abstract: The present disclosure relates generally to compositions and methods for improving T cell therapy. In particular, the disclosure provides polypeptides and recombinant nucleic acid constructs and/or recombinant nucleic acids encoding polypeptides having mutations capable of altering T cell signaling, cytokine production, and/or in vivo persistence in tumors of therapeutic T cells comprising the mutation. The T cell signaling can be by NFAT, NF-?B and/or AP-1 pathways. The disclosure also provides vectors and cells including the polypeptides and/or recombinant nucleic acid constructs and/or recombinant nucleic acids of the disclosure as well as methods of preparing a T cell for use in cell therapy, and methods of identifying a mutation useful for improving T cell therapy.

Abstract: The present disclosure relates generally to compositions and methods for improving T cell therapy. In particular, the disclosure provides polypeptides and recombinant nucleic acid constructs and/or recombinant nucleic acids encoding polypeptides having mutations capable of altering T cell signaling, cytokine production, and/or in vivo persistence in tumors of therapeutic T cells comprising the mutation. The T cell signaling can be by NFAT, NF-?B and/or AP-1 pathways. The disclosure also provides vectors and cells including the polypeptides and/or recombinant nucleic acid constructs and/or recombinant nucleic acids of the disclosure as well as methods of preparing a T cell for use in cell therapy, and methods of identifying a mutation useful for improving T cell therapy.

Abstract: The present disclosure relates generally to compositions and methods for improving T cell therapy. In particular, the disclosure provides polypeptides and recombinant nucleic acid constructs and/or recombinant nucleic acids encoding polypeptides having mutations capable of altering T cell signaling, cytokine production, and/or in vivo persistence in tumors of therapeutic T cells comprising the mutation. The T cell signaling can be by NFAT, NF-?B and/or AP-1 pathways. The disclosure also provides vectors and cells including the polypeptides and/or recombinant nucleic acid constructs and/or recombinant nucleic acids of the disclosure as well as methods of preparing a T cell for use in cell therapy, and methods of identifying a mutation useful for improving T cell therapy.

Abstract: The present disclosure relates generally to compositions and methods for improving T cell therapy. In particular, the disclosure provides polypeptides and recombinant nucleic acid constructs and/or recombinant nucleic acids encoding polypeptides having mutations capable of altering T cell signaling, cytokine production, and/or in vivo persistence in tumors of therapeutic T cells comprising the mutation. The T cell signaling can be by NFAT, NF-?B and/or AP-1 pathways. The disclosure also provides vectors and cells including the polypeptides and/or recombinant nucleic acid constructs and/or recombinant nucleic acids of the disclosure as well as methods of preparing a T cell for use in cell therapy, and methods of identifying a mutation useful for improving T cell therapy.

Abstract: Pairing information is used by the target application to determine how to connect to the correct controller. A network pipe is established between the target application and the controller. The network pipe is used to pass information, such as to deliver/receive test information, between the controller and target application. A bridge may also be established between the controller and an analysis tool for the device hosting the target application. The bridge creates a communication path for the controller to send/receive information (e.g. commands, queries) to the analysis tool s to perform tests of the target application. Code may also be injected into the target application such that dynamic linked libraries may be simulated. Crash data may also be obtained by the controller (or some other device) that may not be typically available by a particular device platform.

Abstract: Pairing information is used by the target application to determine how to connect to the correct controller. A network pipe is established between the target application and the controller. The network pipe is used to pass information, such as to deliver/receive test information, between the controller and target application. A bridge may also be established between the controller and an analysis tool for the device hosting the target application. The bridge creates a communication path for the controller to send/receive information (e.g. commands, queries) to the analysis tool s to perform tests of the target application. Code may also be injected into the target application such that dynamic linked libraries may be simulated. Crash data may also be obtained by the controller (or some other device) that may not be typically available by a particular device platform.